Cargando…

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer

OBJECTIVE: To assess the cost-effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer. METHODS: An analytical decision model was developed to determine the cost-effectiveness of chemohormonal therapy versus androgen deprivatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aguiar, Pedro Nazareth, Barreto, Carmélia Maria Noia, Gutierres, Bárbara de Souza, Tadokoro, Hakaru, Lopes, Gilberto de Lima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto Israelita de Ensino e Pesquisa Albert Einstein 2017
Materias:	Health Economics and Management
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823051/ https://www.ncbi.nlm.nih.gov/pubmed/29091159 http://dx.doi.org/10.1590/S1679-45082017GS4017

Ejemplares similares

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2019)

Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2017)

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer: a review of CDK inhibitors
por: Fernandes, Mariane Teodoro, et al.
Publicado: (2018)

Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
por: Magalhães, Marcos Aurélio Fonseca, et al.
Publicado: (2022)

Disparities in cancer epidemiology and care delivery among Brazilian indigenous populations
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2016)

Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma
por: Jeong, Il Seok Daniel, et al.
Publicado: (2020)

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer
por: Babst, Christa, et al.
Publicado: (2022)

Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer
por: Du, Xinxing, et al.
Publicado: (2023)

Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study
por: Aguiar, Pedro, et al.
Publicado: (2020)

Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
por: Suzuki, Hiroyoshi, et al.
Publicado: (2021)

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer
por: Sugino, Fumiya, et al.
Publicado: (2023)

Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis
por: Huang, Xiaoting, et al.
Publicado: (2020)

Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting
por: Diaby, Vakaramoko, et al.
Publicado: (2020)

Epidemiology and costs of surgical treatment of developmental dysplasia of hip in the Brazilian Public Health System in a decade
por: Souza, Bruno Gonçalves Schröder e, et al.
Publicado: (2021)

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer
por: Sasaki, Takeshi, et al.
Publicado: (2021)

Neoadjuvant Chemohormonal Therapy in Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis
por: Ge, Qingyu, et al.
Publicado: (2022)

Clinical efficacy of neoadjuvant chemohormonal therapy combined with laparoscopic radical prostatectomy in high-risk Prostate Cancer
por: Zhang, Peng, et al.
Publicado: (2022)

Hospitalization costs of severe bacterial pneumonia in children: comparative analysis considering different costing methods
por: Nunes, Sheila Elke Araujo, et al.
Publicado: (2017)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

Comparison of outcomes and costs of surgery versus sclerotherapy to treat hydrocele
por: Korkes, Fernando, et al.
Publicado: (2021)

Spine surgery cost reduction at a specialized treatment center
por: Viola, Dan Carai Maia, et al.
Publicado: (2013)

Implementing technologies to prevent medication errors at a high-complexity hospital: analysis of cost and results
por: Vilela, Renata Prado Bereta, et al.
Publicado: (2019)

CT‐based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration‐naïve oligometastatic prostate cancer
por: Sheikhbahaei, Sara, et al.
Publicado: (2020)

A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
por: Sung, Winnie W. Y., et al.
Publicado: (2021)

Quality Program: what influences the opinion of nursing team
por: da Costa, Fernanda Mazzoni, et al.
Publicado: (2016)

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
por: Liu, Qiao, et al.
Publicado: (2020)

Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review
por: Ong, Sean, et al.
Publicado: (2021)

Treatment of breast cancer patients from a public healthcare system in a private center: costs of care for a pilot public-private partnership in oncology
por: Kaliks, Rafael Aliosha, et al.
Publicado: (2013)

Implementing apportionment strategy to identify costs in a multidisciplinary clinic
por: Ferraz, Renato Ribeiro Nogueira, et al.
Publicado: (2017)

Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
por: Wang, Huijuan, et al.
Publicado: (2020)

Economic analysis of costs with enteral and parenteral nutritional therapy according to disease and outcome
por: Hyeda, Adriano, et al.
Publicado: (2017)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
por: Wu, Yue, et al.
Publicado: (2022)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

Cost estimate of hospital stays for premature newborns of adolescent mothers in a Brazilian public hospital
por: Mwamakamba, Lutufyo Witson, et al.
Publicado: (2014)

Dedicated Education Unit is a cost-effective clinical education model for undergraduate nursing programs
por: dos Santos, Wendel Mombaque, et al.
Publicado: (2020)

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients
por: Sigurdson, Samantha S., et al.
Publicado: (2020)

Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer
por: Korček, Michal, et al.
Publicado: (2020)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u979738diijvbq9giom2f9rgvt